# 510(k) Summary

This summary of the 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is: _K132400

Preparation Date: December 17, 2013

# Applicant Name:

Mr. Joan Guixer   
Director of Quality Assurance and Regulatory Affairs Biokit S.A.   
Telephone number: $( + 3 4 )$ 93 860 90 00   
Fax number: $( + 3 4 )$ 93 860 90 29   
Llica d'Amunt   
Barcelona, Spain 08186   
Device Name:   
Calibrator:   
Classification Name: Calibrator, Secondary   
Trade Name: Lp(a) Calibrators   
Common Name: Calibrator   
Governing Regulation: 21 CFR 862.1150   
Device Classification: Class I1   
Classification Panel: Clinical Chemistry   
Product Code: JIT   
Device Name:   
Control:   
Classification Name: Quality Control Material (assayed and unassayed)   
Trade Name: Lp(a) Control   
Common Name: Single analyte Controls   
Governing Regulation: 21 CFR 862.1660   
Device Classification: Class I, reserved   
Classification Panel: Clinical Chemistry   
Product Code: JJX

# Legally marketed device to which equivalency is claimed:

The Lp(a) Calibrators and Lp(a) Control is substantially equivalent to other products in commercial distribution intended for similar use. We claim equivalence to the currently marketed Quantia Lp(a) Standard and Quantia Lp(a) Control cleared under K050487.

# Intended Use of Device:

The Lp (a) Calibrators are for use in establishing the calibration curve for the Quantia Lp(a) reagents by turbidimetry on the ARCHITECT c Systems.

The Lp (a) Control I and Control II are intended for use as assayed quality control materials for the quantitative monitoring of Lipoprotein (a) with the Quantia Lp(a) reagents by turbidimetry on the ARCHITECT c Systems.

# Description of Device:

The Lp (a) Calibrators are a set of 5 levels required to establish the calibration curve of the Quantia Lipoprotein (a) reagents (K050487) for the quantitative measurement of Lipoprotein (a) concentration in human serum or plasma using immunoturbidimetry technology on the ARCHITECT c Systems.

The Lp (a) Control are a set of 2 levels used to monitor the quantitative measurement of Lipoprotein (a) concentration in human serum or plasma with the Quantia Lipoprotein (a) reagents (K050487) using immunoturbidimetry technology on the ARCHITECT c Systems.

Quantia Lp(a) Reagent included two equivalent reagents presentation that only differ on the geographic distribution zone:

Reference 7K00-40 Quantia Lp(a) Reagent (US) Reference 7K00-01 Quantia Lp(a) Reagent (EX-US)

Both Quantia Lp(a) Reagents reference wil use the Lp(a) Calibrators and Lp(a) Control products.

The human serum used in the Lp(a) Calibrators and Lp(a) Control is nonreactive for HBsAg, anti-HIV-1/HIV-2, and anti-HCV using FDA approved methods.

# Stability

Unopened Lp(a) Calibrators and Lp(a) Control are stable for 32 months when stored at 2 to $8 ^ { \circ } \mathsf { C }$ .

Real time shelf life is determined by comparing results of the calibrators and controls stored at 2 to $8 ^ { \circ } \mathrm { C }$ with their assigned values. The Lp(a) Calibrators and Lp(a) Control were considered stable if the recovery values were within $\pm 1 0 \%$ of the assigned values for controls and calibrators level 2 to 5 and $\pm 3 \mathsf { m g } / \mathsf { d L }$ of assigned value for calibrator level 1.

Once reconstituted, the calibrators and controls are stable for 14 days when stored at 2 to ${ } ^ { 8 \circ } \mathsf { C }$ .

The reconstituted Lp(a) Calibrators and Lp(a) Control were considered stable if the recovery values were within $\pm 1 0 \%$ of the established mean at Day O.

# Value assigment

The value assignment for a new lot of Lp(a) Calibrators involves calibrating the Quantia Lp(a) on the ARCHITECT c8000 Clinical Chemistry System with the existing Master lot and running as samples, each level of the new manufactured calibrator lot, the Master lot and the previously released calibrator lot alternating the measurements until there are a total of 30 replicates for each material at each level.

The Control I and Control Il mean values on the Lp(a) Control Value Sheet were calculated by data generated from multiple runs on the ARCHITECT c8000 System using the Quantia Lp(a) Reagent. The Control I and Control Il target values should be within 10 to 30 mg/dL and 30 to 70 mg/dL respectively. Acceptance ranges are defined as $\pm 2 5 \%$ and $\pm 2 0 \%$ of Control I and Control II target values. The Control I and Control Il lot specific target values and acceptable ranges are indicated on the Lp(a) Control Value Sheet included in the kit. It is recommended that each laboratory should establish its own Target values and Acceptance Range (mean and standard deviation).

# Traceability

No reference material exists for Lp(a) in terms of mg/dL. In-house reference material was value-assigned using a commercial ElA (Enzyme Immunoassay) method.

# Comparison of Technological Characteristics:

The Lp (a) Calibrators and Lp (a) Control are prepared from human sera containing Lp(a) with Kanamycin Monosulfate and Gentamicin Sulfate as preservatives. Both materials are indicated to be used in combination with the QUANTIA Lp(a) (K050487).

The currently marketed Quantia Lp(a) Standard and Quantia Lp(a) Control are prepared from human sera containing Lp(a) with sodium azide as preservative. Both materials are indicated to be used in combination with the QUANTIA Lp(a) (K050487).

# Conclusion

The Lp(a) Calibrators and Lp(a) Control are substantially equivalent to predicate device (K050487).

#

BIOKIT S.A. December 19, 2013   
JOAN GUIXER   
DIRECtOR Of QuALITy AND REGULATORY AFFAIRS   
CAN MALE, S/N   
LLICA d'AMUNT, BARCELONA 08186   
SPAIN

Re: K132400 Trade/Device Name: Lp(a) Calibrators and Lp(a) Controls Regulation Number: 21 CFR 862.1 150 Regulation Name: Calibrator Regulatory Class: II Product Code: JIT, JJX Dated: November 15, 2013 Received: November 18, 2013

Dear Mr. Guixer:

We have reviewed your Section $\pmb { 5 } 1 0 ( \mathbf { k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for u tath cosure) galymarke eicatdevi markee comerce prior to May 28, 1976, the enactment date fthe Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, Csmect (Ac) that o ot equ pval  prearke apoal pplatin (MA). You may, therefore, market the device, subject to the general controls provisions of the Act. The l onts poisnsh c   al trai devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties.We remind you, however, that device labeling must be truthful and not misleading.

I your device isclassed eebove)into either class  (Special ontrols)rclass IMA), it may be subject to additional controls.Existing major regulations affecting your device can be d in the Code f Federal Regulations, Tite , arts 800 to8 In addition, FA ay publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

Page 2â€”Mr. Guixer

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809 please contact the Division of Small Manufacturers, International and Consumer   
Assistance at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address hup://www.fda.gov/MedicalDevices/ResourcesforYou/lndustry/default.htm.Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 7.9.For questions regarding the reporting o adverse events under the MDR regulation CFR Part 803), please go to   
http:/www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, Intemational and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourccsforYou/Industry/default.htm.

Sincerely yours,

Enclosure

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known): K132400

Device Name: Lp(a) Calibrators and Lp(a) Controls

Indications for Use:

# Lp (a) Calibrators

The Lp(a) Calibrators are for use in establishing the calibration curve for the Quantia Lp(a) reagents by turbidimetry on the ARCHITECT c Systems.

# Lp (a) Controls

The Lp(a) Control I and Control Il are intended for use as assayed quality control materials for the quantitative monitoring of Lipoprotein (a) with the Quantia Lp(a) reagents by turbidimetry on the ARCHITECT c Systems.

For in vitro diagnostic use.

# Concurrence of CDRH, Office of In Vitro Diagnostics and Radiological Health (OIR)